Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 6,7-dichloro-5,10-dihydroimidazo[2,1-b]quinazolin-2(3H)-one-2,3,5-13C3
Purity: ≥98%
Formula Markup: C7[13C]3H7Cl2N3O
Formula Weight: 259.1
Notes: Anagrelide-13C3 is intended for use as an internal standard for the quantification of anagrelide (Item No. 21411) by GC- or LC-MS. Anagrelide is an inhibitor of phosphodiesterase 3 (PDE3; IC50 = 36 nM for the human platelet enzyme).{54743} It inhibits thrombopoietin-induced megakaryocytopoiesis of isolated human CD34+ progenitor cells (IC50 = 26 nM).{54744} Anagrelide reduces platelet aggregation induced by ADP, collagen, thrombin, or arachidonic acid (Item Nos. 90010 / 90010.1 / 10006607) in isolated rabbit platelet rich-plasma (EC50s = 0.31, 0.08, 0.18, and 0.1 µg/ml, respectively).{54745} It inhibits platelet thrombus formation in a dog model of electrically induced carotid artery thrombosis when administered at doses ranging from 0.5 to 5 mg/kg.{54746} Formulations containing anagrelide have been used in the treatment of thrombocythemia.
English
Deutsch
